• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Phase II study of copanlisib, a ...
    Size:
    1.207Mb
    Format:
    PDF
    Download
    Authors
    Dreyling, M
    Morschhauser, F
    Bouabdallah, K
    Bron, D
    Cunningham, D
    Assouline, S
    Verhoef, G
    Linton, Kim M
    Thieblemont, C
    Vitolo, U
    Hiemeyer, F
    Giurescu, M
    Garcia-Vargas, J
    Gorbatchevsky, I
    Liu, L
    Koechert, K
    Peña, C
    Neves, M
    Childs, B
    Zinzani, P
    Show allShow less
    Affiliation
    Department of Medicine, Klinikum der Universitat Munchen-Grosshadern, Medizinische Klinik und Poliklinihlk III, Munich, Germany
    Issue Date
    2017-06-14
    
    Metadata
    Show full item record
    Abstract
    Copanlisib is a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor with predominant activity against the α- and δ- isoforms.
    Citation
    Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. 2017 Ann Oncol
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/620448
    DOI
    10.1093/annonc/mdx289
    PubMed ID
    28633365
    Type
    Article
    Language
    en
    ISSN
    1569-8041
    ae974a485f413a2113503eed53cd6c53
    10.1093/annonc/mdx289
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
    • Authors: Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G, Kim WS, Nagler A, Panayiotidis P, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Giurescu M, Cupit L, Liu L, Köchert K, Seidel H, Peña C, Yin S, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL
    • Issue date: 2017 Dec 10
    • Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
    • Authors: Matasar MJ, Capra M, Özcan M, Lv F, Li W, Yañez E, Sapunarova K, Lin T, Jin J, Jurczak W, Hamed A, Wang MC, Baker R, Bondarenko I, Zhang Q, Feng J, Geissler K, Lazaroiu M, Saydam G, Szomor Á, Bouabdallah K, Galiulin R, Uchida T, Soler LM, Cao A, Hiemeyer F, Mehra A, Childs BH, Shi Y, Zinzani PL
    • Issue date: 2021 May
    • Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
    • Authors: Dreyling M, Santoro A, Mollica L, Leppä S, Follows G, Lenz G, Kim WS, Nagler A, Dimou M, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Munoz J, Rodrigues L, Hiemeyer F, Miriyala A, Garcia-Vargas J, Childs BH, Zinzani PL
    • Issue date: 2020 Apr
    • Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives.
    • Authors: Munoz J, Follows GA, Nastoupil LJ
    • Issue date: 2021 May
    • A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.
    • Authors: Grunenberg A, Kaiser LM, Woelfle S, Schmelzle B, Viardot A, Möller P, Barth TFE, Muche R, Dreyhaupt J, Raderer M, Kiesewetter B, Buske C
    • Issue date: 2021 Jun 29
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.